Tarlatamab
- Generic Name
- Tarlatamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2307488-83-9
- Unique Ingredient Identifier
- 74X82ST8Q1
- Associated Conditions
- -
- Associated Therapies
- -
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT06598306
- Locations
- 🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇵🇱Instytut Centrum Zdrowia Matki Polki, Lodz, Poland
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Phase 3
Recruiting
- Conditions
- Extensive-Stage Small-Cell Lung CancerSmall-Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 550
- Registration Number
- NCT06211036
- Locations
- 🇺🇸
Franciscan Health Indianapolis, Indianapolis, Indiana, United States
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, China
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Phase 3
Recruiting
- Conditions
- Limited Stage Small Cell Lung CancerSmall Cell Lung Cancer
- Interventions
- Drug: TarlatamabDrug: Placebo
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT06117774
- Locations
- 🇨🇳
Northern Jiangsu Peoples hospital, Yangzhou, Jiangsu, China
🇨🇳Jiangxi Cancer hospital, Nanchang, Jiangxi, China
🇨🇳The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath